INO stock forecast, quote, news & analysis

Key Takeaways

• Inovio Pharmaceuticals (INO) shares fell roughly 17% over the trailing 30 days, declining from about $1.32 to near $1.09.
• The pullback reflects a give-back of a sharp late-summer recovery rally as investors weigh the upcoming FDA decision on its lead candidate, INO-3107.
• The FDA's Prescription Drug User Fee Act (PDUFA) target action date for INO-3107 remains October 30, 2026, and accelerated-approval eligibility remains a key unresolved question.
• Dilution risk and a limited cash runway remain central concerns, with the company guiding cash into late first quarter 2027.
• Over the last quarter, the stock has traded with extreme volatility, including a sharp July drop tied to a public equity offering.

Inovio Pharmaceuticals (INO) Company Overview and Market Position

Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing DNA medicines designed to treat and protect people from HPV-related diseases, cancer, and infectious diseases. Its platform combines precisely engineered DNA plasmids with a proprietary delivery device called CELLECTRA, which is intended to deliver genetic material into cells without chemical adjuvants or lipid nanoparticles.

The company's lead product candidate is INO-3107, an investigational treatment for recurrent respiratory papillomatosis (RRP), a rare and potentially life-threatening disease caused by HPV. Inovio's pipeline also includes VGX-3100, which targets cervical dysplasia, as well as next-generation DNA-encoded monoclonal antibody and DNA-encoded protein programs. Investors follow the stock closely because the company's valuation is heavily tied to the regulatory and commercial outcome of INO-3107.

Inovio Pharmaceuticals (INO) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, INO shares have fallen approximately 17%, moving from a closing price near $1.32 in early September to about $1.09 in early October. The decline has been relatively steady, with the stock shedding value through late September and into October as bullish momentum from late summer faded.

The broader quarterly picture is more volatile than the headline change suggests. Measured against levels near $1.19 in early July, the stock is down roughly 8% over the last three months. However, that figure masks a dramatic round trip: shares plunged to an intraday low near $0.57 and closed around $0.66 on July 30 following a dilutive public offering, then recovered to a peak near $1.45 in early September before retreating to current levels. The result is a stock that has been range-bound with sharp swings rather than trending decisively in one direction.

What Drove INO Stock Price in the Last 30 Days

The recent decline has been driven by a combination of profit-taking and renewed caution ahead of a pivotal regulatory catalyst. After the stock's sharp recovery from its July lows, investors have been reassessing the risk-reward profile as the October 30, 2026 PDUFA date approaches.

A key overhang is the FDA's stated position on accelerated approval. In its file-acceptance letter, the agency indicated a preliminary conclusion that Inovio had not submitted adequate information to justify eligibility for the accelerated approval pathway for INO-3107. While the company continues to believe it meets the criteria, this unresolved question has kept uncertainty elevated.

Balance-sheet concerns have also weighed on sentiment. Inovio ended the second quarter with $36.7 million in cash, cash equivalents, and short-term investments and has guided that current resources are expected to fund operations into late first quarter 2027. The company's history of dilutive equity offerings, including a July 2026 raise that added roughly 21 million shares, has left investors wary of additional capital raises.

What Drove INO Stock Performance Over the Last Quarter

The defining event of the quarter was the July 30, 2026 collapse tied to a public offering that generated approximately $18.3 million in net proceeds. The addition of more than 21 million shares triggered a sharp single-day selloff as existing shareholders absorbed the dilution.

The stock subsequently recovered, helped by a second-quarter earnings report in mid-August that showed a narrowed net loss of $6.0 million and declining operating expenses, alongside progress on INO-3107. Management confirmed that the FDA had completed its late-cycle review meeting and all scheduled pre-licensure inspections. Separately, partner ApolloBio announced positive top-line Phase 3 results for VGX-3100 in cervical dysplasia, supporting the broader DNA-medicine platform.

Despite these developments, the recovery stalled in September as attention shifted back to the regulatory uncertainty surrounding accelerated approval and the company's ongoing capital needs.

Trending AI Robots

For traders seeking a more systematic approach to volatile names like Inovio, Tickeron's Trending AI Robots page offers a curated view of its algorithmic trading tools. Tickeron operates hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are featured in this section. These bots vary considerably in strategy, timeframe, and performance metrics, allowing users to explore approaches that range from short-term swing signals to longer-horizon trend models. The page is designed to help traders quickly identify AI-driven strategies that are currently generating notable results across the market.

INO Stock Forecast Drivers: What Investors Should Watch Next

The most important near-term catalyst for INO is the FDA's action on the INO-3107 Biologics License Application, with a target action date of October 30, 2026. The outcome—and specifically whether the product receives accelerated approval—will have an outsized influence on the stock's direction.

Investors should also monitor Inovio's cash position and any signs of additional capital-raising activity, given the company's current runway into late first quarter 2027. Commercial execution will matter if INO-3107 is approved, including the ramp of the company's partnership with Syneos Health as its contract sales organization and early launch metrics against the already-marketed competitor Pepzimos. Finally, updates on VGX-3100's regulatory path in China and progress on the company's next-generation DNA medicine platform could shape the longer-term narrative.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations